Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma

This observational study looks at the risks and complications of surgery in people with liver cancer (hepatocellular carcinoma, HCC) who received immunotherapy-based treatment before or to convert their tumor to be resectable. It aims to understand what complications may arise when surgery follows these modern treatments. **You may be eligible if:** - You have been diagnosed with liver cancer (HCC) confirmed by biopsy or clinical criteria - You received immunotherapy-based treatment (neoadjuvant or conversion therapy) before surgery - You have had surgical removal of the tumor and recovered within 4 weeks before enrolling - Your liver function is Child-Pugh A or B (up to 7 points) and you have good general health (ECOG 0-1) - If you have hepatitis B, you are on and willing to continue antiviral treatment **You may NOT be eligible if:** - You did not receive immunotherapy-based treatment before surgery - Your liver function is severely impaired (Child-Pugh C) - You are in poor general health (ECOG 2 or higher) - Your expected survival is less than 12 weeks Talk to your doctor to see if this trial is right for you.